Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Braess

Showing results (31-40 of 84) with videos related to

Pageof 9
Sort By:
Leukemia|April 11, 2023
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemiaChristian Rausch, Maja Rothenberg-Thurley, Annika Dufour, et al.
Leukemia|February 24, 2018
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemiaMaja Rothenberg-Thurley, Susanne Amler, Dennis Goerlich, et al.
Leukemia|August 23, 2025
Quality of life and life satisfaction in long-term survivors of acute myeloid leukemiaEva Telzerow, Dennis Görlich, Cristina Sauerland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative GroupThomas Büchner, Wolfgang E Berdel, Claudia Haferlach, et al.
Haematologica|April 5, 2011
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trialMatthias Stelljes, Dietrich W Beelen, Jan Braess, et al.
Haematologica|September 18, 2012
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapseTim Pfeiffer, Michael Schleuning, Jiri Mayer, et al.
Journal of Cancer Research and Clinical Oncology|February 21, 2020
Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registrySebastian Birndt, Thomas Schenk, Babett Heinevetter, et al.
Blood|July 21, 2012
High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Bernhard Heilmeier, Katrin E Edmaier, et al.
Lancet (London, England)|December 7, 2010
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesUtz Krug, Christoph Röllig, Anja Koschmieder, et al.
Haematologica|June 16, 2018
Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or olderVictoria V Prassek, Maja Rothenberg-Thurley, Maria C Sauerland, et al.
Pageof 9

Showing results (31-40 of 84) with videos related to

Sort By:
Pageof 9
Leukemia|April 11, 2023
Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemiaChristian Rausch, Maja Rothenberg-Thurley, Annika Dufour, et al.
Leukemia|February 24, 2018
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemiaMaja Rothenberg-Thurley, Susanne Amler, Dennis Goerlich, et al.
Leukemia|August 23, 2025
Quality of life and life satisfaction in long-term survivors of acute myeloid leukemiaEva Telzerow, Dennis Görlich, Cristina Sauerland, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2008
Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative GroupThomas Büchner, Wolfgang E Berdel, Claudia Haferlach, et al.
Haematologica|April 5, 2011
Allogeneic transplantation as post-remission therapy for cytogenetically high-risk acute myeloid leukemia: landmark analysis from a single prospective multicenter trialMatthias Stelljes, Dietrich W Beelen, Jan Braess, et al.
Haematologica|September 18, 2012
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapseTim Pfeiffer, Michael Schleuning, Jiri Mayer, et al.
Journal of Cancer Research and Clinical Oncology|February 21, 2020
Hemophagocytic lymphohistiocytosis in adults: collaborative analysis of 137 cases of a nationwide German registrySebastian Birndt, Thomas Schenk, Babett Heinevetter, et al.
Blood|July 21, 2012
High expression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in cytogenetically normal acute myeloid leukemiaKlaus H Metzeler, Bernhard Heilmeier, Katrin E Edmaier, et al.
Lancet (London, England)|December 7, 2010
Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomesUtz Krug, Christoph Röllig, Anja Koschmieder, et al.
Haematologica|June 16, 2018
Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or olderVictoria V Prassek, Maja Rothenberg-Thurley, Maria C Sauerland, et al.
Pageof 9